The first human trial of a gene therapy for choroideremia has announced preliminary results on six people: two of these patients have experienced significant improvements in vision. The findings were published in…Read More
An additional treatment option for people with wet age-related macular degeneration (AMD) will soon be available in Canada. Health Canada has just approved Eyelea, a drug made and marketed by Bayer Inc….Read More
Almost three years ago, scientists at the University of Massachusetts Medical School reported on a preliminary clinical trial of the epilepsy drug, valproic acid, as potential treatment for autosomal dominant retinitis pigmentosa…Read More
Dr. Ian MacDonald and his team at the University of Alberta are internationally recognized experts in the study of choroideremia, a rare blinding disease that typically affects young men beginning in adolescence….Read More
Join the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our eNews.